BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao M, Ding XF, Shen JY, Zhang XP, Ding XW, Xu B. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. J Zhejiang Univ Sci B 2017;18:15-26. [PMID: 28070993 DOI: 10.1631/jzus.B1600303] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Xu J, Wu KJ, Jia QJ, Ding XF. Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B 2020;21:673-89. [PMID: 32893525 DOI: 10.1631/jzus.B1900709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
2 Stoczynska-Fidelus E, Węgierska M, Kierasińska A, Ciunowicz D, Rieske P. Role of Senescence in Tumorigenesis and Anticancer Therapy. J Oncol 2022;2022:5969536. [PMID: 35342397 DOI: 10.1155/2022/5969536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Abdel-Megeed RM, Abd El-Alim SH, Arafa AF, Matloub AA, Farrag AERH, Darwish AB, Abdel-Hamid AZ, Kadry MO. Crosslink among phosphatidylinositol-3 kinase/Akt, PTEN and STAT-5A signaling pathways post liposomal galactomannan hepatocellular carcinoma therapy. Toxicol Rep 2020;7:1531-41. [PMID: 33251120 DOI: 10.1016/j.toxrep.2020.10.018] [Reference Citation Analysis]
4 Olorundare O, Adeneye A, Akinsola A, Kolo P, Agede O, Soyemi S, Mgbehoma A, Okoye I, Albrecht R, Mukhtar H. Irvingia gabonensis Seed Extract: An Effective Attenuator of Doxorubicin-Mediated Cardiotoxicity in Wistar Rats. Oxid Med Cell Longev 2020;2020:1602816. [PMID: 33149803 DOI: 10.1155/2020/1602816] [Reference Citation Analysis]
5 Świętek M, Panchuk R, Skorokhyd N, Černoch P, Finiuk N, Klyuchivska O, Hrubý M, Molčan M, Berger W, Trousil J, Stoika R, Horák D. Magnetic Temperature-Sensitive Solid-Lipid Particles for Targeting and Killing Tumor Cells. Front Chem 2020;8:205. [PMID: 32328477 DOI: 10.3389/fchem.2020.00205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
6 Peixoto R, Pereira ML, Oliveira M. Beta-Blockers and Cancer: Where Are We? Pharmaceuticals (Basel) 2020;13:E105. [PMID: 32466499 DOI: 10.3390/ph13060105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
7 Kyte JA, Røssevold A, Falk RS, Naume B. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer. J Transl Med 2020;18:252. [PMID: 32576225 DOI: 10.1186/s12967-020-02424-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Nel AE, Mei KC, Liao YP, Liu X. Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. ACS Nano 2022. [PMID: 35348320 DOI: 10.1021/acsnano.2c01252] [Reference Citation Analysis]
9 Li WJ, Lian YW, Guan QS, Li N, Liang WJ, Liu WX, Huang YB, Cheng Y, Luo H. Liver-targeted delivery of liposome-encapsulated curcumol using galactosylated-stearate. Exp Ther Med 2018;16:925-30. [PMID: 30112045 DOI: 10.3892/etm.2018.6210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
10 Day CM, Sweetman MJ, Song Y, Plush SE, Garg S. Functionalized Mesoporous Silica Nanoparticles as Delivery Systems for Doxorubicin: Drug Loading and Release. Applied Sciences 2021;11:6121. [DOI: 10.3390/app11136121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Li R, Tian F, Qi Y, Ma L, Zhou T, Li Y, Hui T, Zhang L, Wang S, Song Z. Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052). Sci Rep 2019;9:18135. [PMID: 31792258 DOI: 10.1038/s41598-019-54387-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yang B, Song BP, Shankar S, Guller A, Deng W. Recent advances in liposome formulations for breast cancer therapeutics. Cell Mol Life Sci 2021;78:5225-43. [PMID: 33974093 DOI: 10.1007/s00018-021-03850-6] [Reference Citation Analysis]
13 Hu W, Lv K, Teng R, Chen J, Xu C, Jin L, Chen Y, Zhao W. Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I-III Breast Cancer. Front Genet 2021;12:746114. [PMID: 34616438 DOI: 10.3389/fgene.2021.746114] [Reference Citation Analysis]
14 Tagde P, Najda A, Nagpal K, Kulkarni GT, Shah M, Ullah O, Balant S, Rahman MH. Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management. IJMS 2022;23:2856. [DOI: 10.3390/ijms23052856] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Nechaeva A, Artyukhov A, Luss A, Shtilman M, Gritskova I, Shulgin A, Motyakin M, Levina I, Krivoborodov E, Toropygin I, Chistyakov E, Gurevich L, Mezhuev Y. Synthesis of Amphiphilic Copolymers of N-Vinyl-2-pyrrolidone and Allyl Glycidyl Ether for Co-Delivery of Doxorubicin and Paclitaxel. Polymers 2022;14:1727. [DOI: 10.3390/polym14091727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lérida-Viso A, Estepa-Fernández A, Morellá-Aucejo Á, Lozano-Torres B, Alfonso M, Blandez JF, Bisbal V, Sepúlveda P, García-Fernández A, Orzáez M, Martínez-Máñez R. Pharmacological senolysis reduces doxorubicin-induced cardiotoxicity and improves cardiac function in mice. Pharmacol Res 2022;183:106356. [PMID: 35843569 DOI: 10.1016/j.phrs.2022.106356] [Reference Citation Analysis]
17 Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, Lammers T. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 2018;130:17-38. [PMID: 30009886 DOI: 10.1016/j.addr.2018.07.007] [Cited by in Crossref: 606] [Cited by in F6Publishing: 522] [Article Influence: 151.5] [Reference Citation Analysis]
18 Wang CY, Lin BL, Chen CH. Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3. Cancer Biol Ther 2021;22:12-8. [PMID: 33249980 DOI: 10.1080/15384047.2020.1833156] [Reference Citation Analysis]
19 Tsang YW, Chi KH, Huang CC, Chi MS, Chiang HC, Yang KL, Li WT, Wang YS. Modulated electro-hyperthermia-enhanced liposomal drug uptake by cancer cells. Int J Nanomedicine 2019;14:1269-79. [PMID: 30863059 DOI: 10.2147/IJN.S188791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
20 Ghignatti PVDC, Nogueira LJ, Lehnen AM, Leguisamo NM. Cardioprotective effects of exercise training on doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis of preclinical studies. Sci Rep 2021;11:6330. [PMID: 33737561 DOI: 10.1038/s41598-021-83877-8] [Reference Citation Analysis]
21 Qiao EQ, Yang HJ, Zhang XP. Screening of miRNAs associated with lymph node metastasis in Her-2-positive breast cancer and their relationship with prognosis. J Zhejiang Univ Sci B 2020;21:495-508. [PMID: 32478495 DOI: 10.1631/jzus.B1900584] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Yi GY, Kim MJ, Kim HI, Park J, Baek SH. Hyperthermia Treatment as a Promising Anti-Cancer Strategy: Therapeutic Targets, Perspective Mechanisms and Synergistic Combinations in Experimental Approaches. Antioxidants 2022;11:625. [DOI: 10.3390/antiox11040625] [Reference Citation Analysis]
23 Liu X, Zhou XQ, Shang XW, Wang L, Li Y, Yuan H, Hu FQ. Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment. J Zhejiang Univ Sci B 2020;21:218-33. [PMID: 32133799 DOI: 10.1631/jzus.B1900468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
24 Rivier C, Mery B, Rowinski E, Sotton S, Bouleftour W, Bertoletti L, Tredan O, Magne N. Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. Expert Opin Drug Saf 2021;:1-13. [PMID: 34551666 DOI: 10.1080/14740338.2021.1983541] [Reference Citation Analysis]